

1 Amend 17 Cal. Code of Regs. section 100070 to read:

2 **§ 100070. SCRO Committee Review and Notification.**

3 (a) CIRM-funded research involving the procurement or use of human oocytes may not  
4 commence without SCRO committee review and approval in writing. For such SCRO  
5 committee review and approval, a member of the committee with expertise in assisted  
6 reproduction shall be present. The designated SCRO committee may require that modification be  
7 made to proposed research or documentation of compliance with the requirements of subdivision  
8 (a)(3) of this regulation as a condition of granting its approval. At a minimum, the SCRO  
9 committee shall require the investigator to:

10 (1) Provide an acceptable scientific rationale for the need to use oocytes  
11 including a justification for the number needed. If SCNT is proposed a justification for  
12 SCNT shall be provided.

13 (2) Demonstrate experience, expertise or training in derivation or culture of  
14 human or nonhuman stem cell lines.

15 (3) Provide documentation of compliance with any required review of the  
16 proposed research by an IRB, Institutional Animal Care and Use Committee (IACUC),  
17 Institutional Bioethics Committee (IBC), or other mandated review.

18 (b) CIRM-funded research involving use of human embryos may not commence without  
19 SCRO committee review and approval in writing. The designated SCRO committee may  
20 require that modification be made to proposed research or documentation of compliance with the  
21 requirements of subdivision (b)(3) of this regulation as a condition of granting its approval. At a

1 minimum, the SCRO committee shall require the investigator to:

2 (1) Provide an acceptable scientific rationale for the need to use embryos

3 including a justification for the number needed.

4 (2) Demonstrate experience, expertise or training in derivation or culture of

5 human or nonhuman stem cell lines.

6 (3) Provide documentation of compliance with any required review of the

7 proposed research by an IRB, Institutional Animal Care and Use Committee (IACUC),

8 Institutional Bioethics Committee (IBC), or other mandated review.

9 (c) CIRM-funded research with the aim to derive or create a covered stem cell line from

10 human gametes, embryos or products of SCNT involving a human donor nucleus may not

11 commence without SCRO committee review and approval in writing. The designated SCRO

12 committee may require that modification be made to proposed research or documentation of

13 compliance with the requirements of subdivision (c)(4) of this regulation as a condition of

14 granting its approval. At a minimum, the SCRO committee shall require the investigator to:

15 (1) Provide an acceptable scientific rationale for the need to derive a covered

16 stem cell line.

17 (2) If SCNT is proposed as a route to generating human stem cell lines, a

18 justification for SCNT shall be provided.

19 (3) Demonstrate experience, expertise or training in derivation or culture of

20 human or nonhuman stem cell lines.

21 (4) Provide documentation of compliance with any required review of the

1 proposed research by an IRB, Institutional Bioethics Committee (IBC), or other  
2 mandated review.

3 (5) Document how stem cell lines will be characterized, validated, stored, and distributed  
4 to ensure that the confidentiality of the donor(s) is protected.

5 (d) CIRM-funded purely in vitro research utilizing covered stem cell lines or the  
6 reprogramming of human somatic cells with the aim to derive or create a covered stem cell line  
7 may not commence without written notification to the designated SCRO committee. Research  
8 may include animal assays to evaluate pluripotency; however, subsequent introduction of derived  
9 covered stem cell lines in non-human animals shall be reviewed in accordance with subdivision  
10 (e) of this regulation. At a minimum, the notification shall:

11 (1) Provide assurance that all covered stem cell lines have been acceptably  
12 derived.

13 (2) Provide documentation of compliance with any required review of the  
14 proposed research by an IRB, IACUC, IBC, or other mandated review.

15 (e) CIRM-funded research introducing covered stem cell lines into non-human animals  
16 or introducing neural-progenitor cells into the brain of non-human animals at any state of  
17 embryonic, fetal, or postnatal development may not commence without SCRO committee review  
18 and approval in writing. The designated SCRO committee may require that modification be  
19 made to proposed research or documentation of compliance with the requirements of subdivision  
20 (e)(3) of this regulation as a condition of granting its approval. The SCRO committee may  
21 establish guidelines and procedures for expedited review of animal research so that review by the

**Agenda Item # 13 B**  
**1/30/09 ICOC Meeting**

1 entire SCRO committee is not required. At a minimum, the SCRO committee shall require the  
2 investigator to:

3 (1) Provide an acceptable scientific rationale for introducing stem cells into non-  
4 human animals.

5 (2) Provide assurance that all covered stem cell lines have been acceptably  
6 derived.

7 (3) Evaluate the probable pattern and effects of differentiation and integration of  
8 the human cells into the nonhuman animal tissues.

9 (4) Provide documentation of compliance with any required review of the  
10 proposed research by an IRB, IACUC, IBC, or other mandated review.

11 (f) CIRM-funded research introducing cells from covered stem cell lines into a live born  
12 human may not commence without SCRO committee review and approval in writing. The

13 designated SCRO committee may require that modification be made to proposed research or  
14 documentation of compliance with the requirements of subdivision (f)(4) of this regulation as a

15 condition of granting its approval. At a minimum, the SCRO committee shall require the  
16 investigator to:

17 (1) Provide an acceptable scientific for rationale introducing stem cells into  
18 humans.

19 (2) Provide assurance that all covered stem cell lines have been acceptably  
20 derived.

21 (3) Evaluate the probable pattern and effects of differentiation and integration of

Scott Tocher 1/26/09 11:34 AM

Deleted: stem

**Agenda Item # 13 B**  
**1/30/09 ICOC Meeting**

1 the human cells into the human tissues.

2 (4) Provide documentation of compliance with any required review of the  
3 proposed research by an IRB, IACUC, IBC, or other mandated review.

4 (g) In cases where SCRO committee approval is required, a SCRO committee shall  
5 notify investigators in writing of its decision to approve or disapprove the proposed research  
6 activity, or of modifications required to secure SCRO committee approval of the research  
7 activity. If the SCRO committee decides to disapprove a research activity, it shall include in its  
8 written notification a statement of the reasons for its decision and give the investigator an  
9 opportunity to respond in person or in writing.

10 (h) SCRO committee approvals shall be reviewed no less frequently than once per year.  
11 The renewal review shall confirm compliance with all applicable rules and regulations. The  
12 SCRO committee may establish guidelines and procedures for expedited review of renewals so  
13 that review by the entire SCRO committee is not required.

14 Note: Authority cited: Article XXXV, California Constitution; Section 125290.40(j), Health and

15 Safety Code. Reference: Sections 125290.40, 125290.55, Health and Safety Code.

STocher 10/16/06 1:20 PM

Deleted: 4